Case Report: Subcutaneous ofatumumab for patients with immunosuppressant-dependent or ineffective primary membranous nephropathy

Case Report: Subcutaneous ofatumumab for patients with immunosuppressant-dependent or ineffective primary membranous nephropathy

CD20 monoclonal antibodies (mAbs), particularly rituximab, have become a preferred treatment for many patients with phospholipase A2 receptor (PLA2R)-related membranous nephropathy (MN). However, some patients either fail to respond to rituximab or experience adverse reactions, indicating that newer...

Full description

Saved in:
Bibliographic Details
Main Authors: Jie Chen, De-tian Li, Xin Feng, Bei-Ru Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Immunology
Subjects:
ofatumumab
membrane nephropathy
PLA2R antibody
subcutaenous administration
CD20 monoclonal antibody
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1610530/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items